Thalidomide metabolism and hydrolysis: Mechanisms and implications

Current Drug Metabolism

Volumn 7, Issue 6, 2006, Pages 677-685

  Lepper, Erin R ^a   Smith, Nicola F ^b   Cox, Michael C ^b   Scripture, Charity D ^b   Figg, William D ^b  

^a SAIC FREDERICK INC   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

CYP2C19; Hydrolysis; Hydroxylation; Pharmacokinetics

Indexed keywords

2 (O CARBOXYBENZAMIDO)GLUTARAMIC ACID; 2 (O CARBOXYBENZAMIDO)GLUTARIC ACID; 2 PHTHALIMIDOGLUTARAMIC ACID; 4 (O CARBOXYBENZAMIDO)GLUTARAMIC ACID; ALPHA AMINOGLUTARIMIDE; CYTOCHROME P450 1A; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2B; CYTOCHROME P450 2B6; CYTOCHROME P450 2C11; CYTOCHROME P450 2C12; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 4A; DOCETAXEL; DRUG METABOLITE; GLUTAMIC ACID; GLUTAMINE; PHTHALIC ACID; PHTHALOYLGLUTAMINE; PHTHALOYLISOGLUTAMIC ACID; PHTHALOYLISOGLUTAMINE; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANGIOGENESIS; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; CANCER; CLINICAL TRIAL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYDROLYSIS; DRUG HYDROXYLATION; DRUG MECHANISM; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; DRUG URINE LEVEL; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; INFLAMMATORY DISEASE; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; NONHUMAN; PHARMACOGENETICS; PHENOTYPE; PROSTATE CANCER; REVIEW; SPECIES DIFFERENCE; TERATOGENICITY;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTI-INFLAMMATORY AGENTS; CYCLOOXYGENASE 2 INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; HUMANS; HYDROLYSIS; PHARMACOGENETICS; THALIDOMIDE;

EID: 33747174832     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920006778017777     Document Type: Review

References (63)

1. Teo, S. K., Stirling, D. I. and Zeldis, J. B. (2005) Drug Discov. Today 10(2), 107-114.
2. Franks, M. E., Macpherson, G. R. and Figg, W. D. (2004) Lancet 363(9423), 1802-1811.
3. D'Amato, R. J., Loughnan, M. S., Flynn, E. and Folkman, J. (1994) Proc. Natl. Acad. Sci. USA 91(9), 4082-4085.
4. Bauer, K. S., Dixon, S. C. and Figg, W. D. (1998) Biochem. Pharmacol. 55(11), 1827-1834.
5. Fujita, K., Asami, Y., Murata, E., Akita, M. and Kaneko, K. (2002) Okajimas Folia Anat. Jpn. 79(4), 101-106.
6. Marks, M. G., Shi, J., Fry, M. O., Xiao, Z., Trzyna, M., Pokala, V., Ihnat, M. A. and Li, P. K. (2002) Biol. Pharm. Bull. 25(5), 597-604.
7. Kenyon, B. M.. Browne. F. and D'Amato. R. J. (1997) Exp. Eye Res. 64(6), 971-978.
8. Vacca, A., Scavelli, C., Montefusco, V., Di, Pietro, G., Neri, A., Mattioli, M., Bicciato, S., Nice, B., Ribatti, D., Dammacco, F. and Corradini, P. (2005) J. Clin. Oncol. 5334-46.
9. Yabu, T., Tomimoto, H., Taguchi, Y., Yamaoka, S., Igarashi, Y. and Okazaki, T. (2005) Blood 106(1), 125-134.
10. Hansen, J. M. and Harris, C. (2004) Antioxid. Redox. Signal. 6(1), 1-14.
11. Sauer, H., Gunther, J., Hescheler, J. and Wartenberg, M. (2000) Am. J. Pathol. 156(1), 151-158.
12. Stephens, T. D., Bunde, C. J. and Fillmore, B. J. (2000) Biochem. Pharmacol. 59(12), 1489-1499.
13. Miyata, M., Tamura, E., Motoki, K., Nagata, K. and Yamazoe, Y. (2003) Drug Metab. Dispos. 31(4), 469-475.
14. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M. and Du-Bois, R. N. (1998) Cell 93(5), 705-716.
15. Fujita, J., Mestre, J. R., Zeldis, J. B., Subbaramaiah, K. and Dannenberg, A. J. (2001) Clin. Cancer Res. 7(11), 3349-3355.
16. Du, G. J., Lin, H. H., Xu, Q. T. and Wang, M. W. (2005) Vascul. Pharmacol.
17. Payvandi, F., Wu, L., Haley, M., Schafer, P. H., Zhang, L. H., Chen, R. S., Muller, G. W. and Stirling, D. I. (2004) Cell Immunol 230(2), 81-88.
18. von Knethen, A., Callsen, D. and Brune, B. (1999) J. Immunol. 163(5), 2858-2866.
19. Meierhofer, C., Dunzendorfer, S. and Wiedermann, C. J. (2001) BioDrugs 15(10), 681-703.
20. Shannon, E. J. and Sandoval, F. (1996) Immunopharmacol. Immunotoxicol. 18(1), 59-72.
21. Moreira, A. L., Sampaio, E. P., Zmuidzinas, A., Frindt, P., Smith, K. A. and Kaplan, G. (1993) J. Exp. Med. 177(6), 1675-1680.
22. Boutten, A., Dehoux, M., Deschenes, M., Rouzeau, J. D., Bories, P. N. and Durand G. (1992) Eur. J. Immunol. 22(10), 2687-2695.
23. Turk, B. E., Jiang, H. and Liu, J. O. (1996) Proc. Natl. Acad. Sci. USA 93(15), 7552-7556.
24. Wnendt, S., FinkAm. M., Winter, W., Ossig, J., Raabe, G. and Zwingenberger, K. (1996) Chirality 8(5), 390-396.
25. Sampaio, E. P., Kaplan, G., Miranda, A., Nery, J. A., Miguel, C. P., Viana, S. M. and Samo, E. N. (1993) J. Infect. Dis. 168(2), 408-414.
26. Haslett, P. A., Corral, L. G., Albert, M. and Kaplan, G. (1998) J. Exp. Med. 187(11), 1885-1892.
27. Davies, F. E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y. T., Lin, B., Podar, K., Gupta, D., Chauhan, D., Treon, S. P., Richardson, P. G., Schlossman, R. L., Morgan, G. J., Muller, G. W., Stirling, D. I. and Anderson, K. C. (2001) Blood 98(1), 210-216.
28. Keifer, J. A., Guttridge, D. C., Ashburner, B. P. and Baldwin, A. S., Jr. (2001) J. Biol. Chem. 276(25), 22382-22387.
29. Williams, R. T. and Parke, D. V. (1964) Ann. Rev. Pharmacol. 4, 85-114.
30. Chung, F., Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Tingle, M. and Ching, L. M. (2004) Clin. Cancer Res. 10(17), 5949-5956.
31. Beckmann, R. (1963) Arzneimittelforschung 13, 185-191.
32. Jonsson, N. A. (1972) Acta Pharm. Suec. 9(6), 521-542.
33. Keberle, H., Faigle, J. W., Fritz, H., Knusel, F., Loustalot, P. and Schmid, K. Embryopathic Activity of Drugs. London: Churchill, 1965.
34. Schumacher, H., Smith, R. L. and Williams, R. T. (1965) Br. J. Pharmacol. 25(2), 324-337.
35. Williams, R. T., Schumacher, H., Fabro, S. and Smith, R. L. Embryopathic Activity of Drugs. London: Churchill, 1965.
36. Fabro, S., Schumacher, H., Smith, R. L., Stagg, R. B. and Williams, R. T. (1965) Br. J. Pharmacol. 25(2), 352-362.
37. Lepper, E. R., Ng, S. S., Gutschow, M., Weiss, M., Hauschildt, S., Hecker, T. K., Luzzio, F. A., Eger, K. and Figg, W. D. (2004) J. Med. Chem. 47(9), 2219-2227.
38. Gordon, G. B., Spielberg, S. P., Blake, D. A. and Balasubramanian, V. (1981) Proc. Natl. Acad. Sci. USA 78(4), 2545-2548.
39. Weinz, C. and Blaschke, G. (1995) J. Chromatogr. B. Biomed. Appl. 674(2), 287-292.
40. Meyring, M., Muhlbacher, J., Messer, K., Kastner-Pustet, N., Bringmann, G., Mannschreck, A. and Blaschke, G. (2002) Anal. Chem. 74(15), 3726-3735.
41. Meyring, M., Muhlenbrock, C. and Blaschke, G. (2000) Electrophoresis 21(15), 3270-3279.
42. Lu, J., Palmer, B. D., Kestell, P., Browett, P., Baguley, B. C., Muller, G. and Ching, L. M. (2003) Clin. Cancer Res. 9(5), 1680-1688.
43. Eriksson, T., Bjorkman, S., Roth, B., Bjork, H. and Hoglund, P. (1998) J. Pharm. Pharmacol. 50(12), 1409-1416.
44. Teo, S. K., Sabourin, P. J., O'Brien, K., Kook, K. A. and Thomas, S. D. (2000) J. Biochem. Mol. Toxicol. 14(3), 140-147.
45. Ando, Y., Price, D. K., Dahut, W. L., Cox, M. C., Reed, E. and Figg, W. D. (2002) Cancer Biol. Ther. 1(6), 669-673.
46. Braun, A. G., Harding, F. A. and Weinreb, S. L. (1986) Toxicol. Appl. Pharmacol. 82(1), 175-179.
47. Ando, Y., Fuse, E. and Figg, W. D. (2002) Clin. Cancer Res. 8(6), 1964-1973.
48. Lu, J., Helsby, N., Palmer, B. D., Tingle, M., Baguley, B. C., Kestell, P. and Ching, L. M. (2004) J. Pharmacol. Exp. Ther. 310(2), 571-577.
49. Price, D. K., Ando, Y., Kruger, E. A., Weiss, M. and Figg, W. D. (2002) Ther. Drug Monit. 24(1), 104-110.
50. Ng, S. S., Gutschow, M., Weiss, M., Hauschildt, S., Teubert, U., Hecker, T. K., Luzzio, F. A., Kruger, E. A., Eger, K. and Figg, W. D. (2003) Cancer Res. 63(12), 3189-3194.
51. Ng, S. S., Macpherson, G. R., Gutschow, M., Eger, K. and Figg, W. D. (2004) Clin. Cancer Res. 10(12 Pt 1), 4192-4197.
52. Teo, S. K., Colburn, W. A. and Thomas, S. D. (1999) J. Clin. Pharmacol. 39(11), 1162-1168.
53. Teo, S. K., Scheffler, M. R., Kook, K. A., Tracewell, W. G., Colburn, W. A., Stirling, D. I. and Thomas, S. D. (2000) Biopharm. Drug Dispos. 21(1), 33-40.
54. Piscitelli, S. C., Figg, W. D., Hahn, B., Kelly, G., Thomas, S. and Walker, R. E. (1997) Antimicrob. Agents Chemother. 41(12), 2797-2799.
55. Noormohamed, F. H., Youle, M. S., Higgs, C. J., Kook, K. A., Hawkins, D. A., Lant, A. F. and Thomas, S. D. (1999) AIDS Res. Hum. Retroviruses 15(12), 1047-1052.
56. Wohl, D. A., Aweeka, F. T., Schmitz, J., Pomerantz, R., Cherng, D.W., Spritzler, J., Fox, L., Simpson, D., Bell, D., Holohan, M. K., Thomas, S., Robinson, W., Kaplan, G. and Teppler, H. (2002) J. Infect. Dis. 185(9), 1359-1363.
57. Aweeka, F., Trapnell, C., Chernoff, M., Jayewardene, A., Spritzler, J., Bellibas, S. E., Lizak, P. and Jacobson, J. (2001) J. Clin. Pharmacol. 41(10), 1091-1097.
58. Figg, W. D., Raje, S., Bauer, K. S., Tompkins, A., Venzon, D., Bergan, R., Chen, A., Hamilton, M., Pluda, J. and Reed, E. (1999) J. Pharm. Sci. 88(1), 121-125.
59. Dal, Lago, L., Richter, M. F., Cancela, A. I., Fernandes, S. A., Jung, K. T., Rodrigues, A. C., Costa, T. D., Di, Leone, L. P. and Schwartsmann, G. (2003) Invest. New Drugs 21(3), 359-366.
60. Fakhouri, F., Guerraoui, H., Presne, C., Peltier, J., Delarue, R., Muret, P. and Knebelmann, B. (2004) Br. J. Haematol. 125(1), 96-97.
61. Eriksson, T., Hoglund, P., Turesson, I., Waage, A., Don, B. R., Vu, J., Scheffler, M. and Kaysen, G. A. (2003) J. Pharm. Pharmacol. 55(12), 1701-1706.
62. Ingelman-Sundberg, M. (2005) Toxicol. Appl. Pharmacol.
63. Williams, M. L., Bhargava, P., Cherrouk, I., Marshall, J. L., Flockhart, D. A. and Wainer, I. W. (2000) Br. J. Clin. Pharmacol. 49(5), 485-488.